Digesting the doughnut hole

Journal of Health Economics

Volumn 32, Issue 6, 2013, Pages 1345-1355

  Joyce, Geoffrey F ^a   Zissimopoulos, Julie ^a   Goldman, Dana P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Coverage gap; Insurance Design, Price Elasticity; Medicare Part D; Prescription Drugs

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENERIC DRUG; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; OPIATE; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG;

DIABETES; DRUG; ELASTICITY; HEALTH INSURANCE; HEALTH SERVICES; NERVOUS SYSTEM; PRICE DYNAMICS;

AGED; ARTICLE; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG USE; FEMALE; HEALTH CARE NEED; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; COMPARATIVE STUDY; DECISION MAKING; ECONOMICS; EMPIRICAL RESEARCH; INSURANCE; LEGISLATION AND JURISPRUDENCE; MEDICATION COMPLIANCE; ORGANIZATION AND MANAGEMENT; UNITED STATES;

AGED; CHOICE BEHAVIOR; DRUG COSTS; EMPIRICAL RESEARCH; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; MEDICARE PART D; MEDICATION ADHERENCE; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84888865626     PISSN: 01676296     EISSN: 18791646     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2013.04.007     Document Type: Article

References (21)

1. Chandra, A., Gruber, J. et al., 2007. Patient cost-sharing, hospitalization offsets, and the design of optimal health insurance for the elderly. National Bureau of Economic Research, Inc, NBER Working Papers 12972.
2. Fairman K.A., Motheral B.R., et al. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clinical Therapeutics 2003, 25(12):3147-3161. discussion 3144-3146.
3. Gaynor M., Li J., et al. Substitution, spending offsets, and prescription drug benefit design. Forum for Health Economics and Policy 2007, 10(2).
4. Hoadley J., Summer L., et al. Understanding the effects of the Medicare Part D coverage gap in 2008 and 2009: Costs and consequences prior to improvements in coverage established by the 2010 Health Reform Law. Program on Medicare Policy 2011, 1-46. The Kaiser Family Foundation.
5. Hsu J., Fung V., et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. Journal of the American Medical Association 2008, 299(16):1929-1936.
6. Hsu J., Price M., et al. Unintended consequences of caps on Medicare drug benefits. New England Journal of Medicine 2006, 354(22):2349-2359.
7. Johnson R.E., Goodman M.J., et al. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Medical Care 1997, 35(11):1119-1131.
8. Joyce G.F., Goldman D.P., et al. Medicare Part D after 2 years. American Journal of Managed Care 2009, 15(8):536-544.
9. Kaestner R., Khan N. Medicare Part D and its effect on the use of prescription drugs and use of other health care services of the elderly. Journal of Policy Analysis and Management 2012, 31(2):253-279.
10. Kaiser Family Foundation The Medicare prescription drug benefit. Fact Sheet. K. F. Foundation 2011, Kaiser Family Foundation, Washington, DC.
11. Ketcham J.D., Simon K.I. Medicare Part D's effects on elderly patients' drug costs and utilization. American Journal of Managed Care 2008, 14(11 Suppl.):SP14-SP22.
12. Levy H., Weir D. The impact of Medicare Part D on drug utilization and out-of-pocket spending: Evidence from the health and retirement study 2008.
13. Lichtenberg F.R., Sun S.X. The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs 2007, 26(6):1735-1744.
14. McWilliams J.M., Zaslavsky A.M., et al. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. Journal of the American Medical Association 2011, 306(4):402-409.
15. Motheral B., Fairman K.A. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Medical Care 2001, 39(12):1293-1304.
16. Polinski J.M., Shrank W.H., et al. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Medicine 2011, 8(8):e1001075.
17. Research K. Seniors' Opinions About Medicare Rx: Sixth Year Update. K. Research 2011, KRC Research, Washington, DC.
18. Tseng C.W., Brook R.H., et al. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. Journal of the American Medical Association 2004, 292(8):952-960.
19. Yin W., Basu A., et al. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Annals of Internal Medicine 2008, 148(3):169-177.
20. Zhang Y., Donohue J.M., et al. The effect of Medicare Part D on drug and medical spending. New England Journal of Medicine 2009, 361(1):52-61.
21. Zhang Y., Donohue J.M., et al. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Affairs 2009, 28(2):w317-w325.